SOHO 2022 | The importance of FLT3 inhibitors in AML and factors to consider when choosing between these agents
In this video, Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the role of FLT3 inhibitors in the treatment of acute myeloid leukemia (AML), and important factors to consider when choosing between these agents. First, Dr Kadia highlights how the AML treatment landscape has improved over the years with the approval of novel agents, and then goes on to explain the value of various FLT3 inhibitors, including midostaurin, quizartinib, and gilteritinib. Following this, Dr Kadia explains disease-related and patient-related factors to consider when selecting between FLT3 inhibitors. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
